235 related articles for article (PubMed ID: 32321912)
1. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
Huang HH; Ferguson ID; Thornton AM; Bastola P; Lam C; Lin YT; Choudhry P; Mariano MC; Marcoulis MD; Teo CF; Malato J; Phojanakong PJ; Martin TG; Wolf JL; Wong SW; Shah N; Hann B; Brooks AN; Wiita AP
Nat Commun; 2020 Apr; 11(1):1931. PubMed ID: 32321912
[TBL] [Abstract][Full Text] [Related]
2. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
3. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
Wang Z; Dove P; Wang X; Shamas-Din A; Li Z; Nachman A; Oh YJ; Hurren R; Ruschak A; Climie S; Press B; Griffin C; Undzys E; Aman A; Al-awar R; Kay LE; O'Neill D; Trudel S; Slassi M; Schimmer AD
Cell Death Dis; 2015 Jul; 6(7):e1815. PubMed ID: 26158521
[TBL] [Abstract][Full Text] [Related]
4. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
Pilch B; Allemand E; Facompré M; Bailly C; Riou JF; Soret J; Tazi J
Cancer Res; 2001 Sep; 61(18):6876-84. PubMed ID: 11559564
[TBL] [Abstract][Full Text] [Related]
5. Targeting the spliceosome machinery: A new therapeutic axis in cancer?
Eymin B
Biochem Pharmacol; 2021 Jul; 189():114039. PubMed ID: 32417188
[TBL] [Abstract][Full Text] [Related]
6. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
7. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS
Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
11. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
12. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
13. The Natural Product N-Palmitoyl-l-leucine Selectively Inhibits Late Assembly of Human Spliceosomes.
Effenberger KA; James RC; Urabe VK; Dickey BJ; Linington RG; Jurica MS
J Biol Chem; 2015 Nov; 290(46):27524-31. PubMed ID: 26408199
[TBL] [Abstract][Full Text] [Related]
14. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.
Schäfer J; Welti L; Seckinger A; Burhenne J; Theile D; Weiss J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):71-79. PubMed ID: 28500557
[TBL] [Abstract][Full Text] [Related]
15. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak AJ
Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
[TBL] [Abstract][Full Text] [Related]
16. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
17. Blocking late stages of splicing quickly limits pre-spliceosome assembly in vivo.
Mendoza-Ochoa GI; Barrass JD; Maudlin IE; Beggs JD
RNA Biol; 2019 Dec; 16(12):1775-1784. PubMed ID: 31671032
[TBL] [Abstract][Full Text] [Related]
18. The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
[TBL] [Abstract][Full Text] [Related]
19. New orally active proteasome inhibitors in multiple myeloma.
Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib.
Kortuem KM; Stewart AK
Blood; 2013 Feb; 121(6):893-7. PubMed ID: 23393020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
